Navigation Links
A New Target for Painkillers: Snail Toxins Show the Way

A brand new approach to treating severe nerve pain – by aiming drugs at a previously unrecognized molecular target – has been discovered //by University of Utah scientists who study the venoms of deadly, sea-dwelling cone snails.

“We found a new way to treat a chronic and debilitating form of pain suffered by hundreds of millions of people on Earth,” says J. Michael McIntosh, a University of Utah research professor of biology, and research director and professor in the Department of Psychiatry. “It is a previously unrecognized mechanism for treating pain.”

The findings are being published the week of Nov. 13 in the online edition of the journal Proceedings of the National Academy of Sciences.

The study in rats found that cone snail toxins named RgIA and Vc1.1 can treat nerve hypersensitivity and pain by blocking a molecule in cells known as the “alpha9alpha10 nicotinic acetylcholine receptor.”

“The numerous analgesic compounds currently available are largely ineffective” for chronic nerve pain, McIntosh and colleagues write. “Our findings not only suggest a previously unrecognized molecular mechanism for the treatment of neuropathic pain, but also demonstrate the involvement of alpha9alpha10 nicotinic receptors” in nerve injury.

McIntosh emphasized neither substance will be on the market soon. Vc1.1, also known as ACV1, is being developed by an Australian company, Metabolic, and is undergoing trials of its effectiveness in human patients. While Metabolic has said the drug targets nicotinic receptors, McIntosh says alpha9alpha10 nicotinic receptors have not been reported previously as a target for any kind of painkilling medication. McIntosh says Vc1.1 is administered by subcutaneous (under the skin) injection.

McIntosh hopes the new findings make it feasible to develop a painkiller based on RgIA that could be taken orally, but he believes that will take at least 10 years.

Source-ewswi
'"/>




Page: 1 2

Related medicine news :

1. Target for obesity treatment
2. Gel Offers A More Targeted Approach
3. In Search Of A New Drug To Target Cholesterol
4. In Search Of A New Drug To Target Cholesterol
5. Target of diabetes type 1 identified
6. Gene Target For Tuberculosis Identified
7. New Vaccine Targeted At Effective Treatment Against Tuberculosis
8. Novel Technique For Targeting Small-Cell Lung Cancer
9. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
10. Doctors, Pharma Companies Targeted By CBI Raids
11. Research Targets treatment for dementia and brain injuries
Post Your Comments:
(Date:12/2/2008)...tCall/ -- Quest Diagnostics Incorporated (NYSE: ...testing, information and services, announced that ...thcare Conference in New York City today, December...cheduled to begin at 4:00 p.m. Eastern Time. , ...affirm its 2008 guidance for revenue growth of gre...
(Date:12/2/2008)...er with aprotinin, a drug commonly used to control...y, compared with lysine analogues, according to a ...9 to be published in the January 20th issue of C...dvisory panel will meet to decide on aprotinin use...the meeting. , The study, a systematic review o...
(Date:12/2/2008)...rstCall/ - NUCRYST Pharmaceuticals Corp., a develo...t infection and inflammation, announced today that...rity shareholder, The Westaim Corporation ("Westai...areholders to consider a return of capital of US$0...s to a return of capital of approximately US$15 mi...
(Date:12/2/2008)...e Efficacy of Commercially Available Hypomethylati... Eisai Corporation of North Americ...rst clinical trial evaluating the activity of Daco...za(R) (azacitidine) in adult patients with interme...ic syndromes (MDS), a potentially life-threatening...
Breaking Medicine News(10 mins):Health News:Quest Diagnostics to Speak at the 20th Annual Piper Jaffray Healthcare Conference 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 2Health News:NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder 3Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3
... of Public Health have reported that over the coun...eneficial as they can lower the risk of Parkinson’... took daily one ibuprofen tablet, men and women, f...eople seemed to have a 38% less chance of having P...
... increased calcium intake by drinking milk or othe...of Parkinson’s disease. Parkinson’s disease is a d...s are muscle tremors, muscle rigidity, decreased m...low voluntary movements, and a mask-like facial ex...
... out how to elevate the functional limitations of ...e researchers of Feinberg School of Medicine, US ...and old with arthritis. Functions, which were chec...ng to daily living and specialized activities of d...
...ncy is associated with dental problems. But are th...trong enough to affect the babies’ birth weight or...ew York University College of Dentistry, US, say t...a affect the pregnancy by causing pre-term deliver...
Other Medicine News:
(Date:12/1/2008)...e Call Scheduled for Tuesday, December 9 at 11:00 ..., , SOUTH SAN FRANCISCO, Calif., Dec. 1 /...Inc. (Nasdaq: SNSS ), a biopharmaceutical compan... of new oncology therapeutics, today announced new...id leukemia (AML) will be presented during the 50t...
(Date:11/28/2008)..., Germany, November 28 German biot...ship in specialized HIV monitoring and,AIDS patie...ng countries. In,the year 2008, 2.5 million patie...obust and highly affordable "CyFlow" system, suppo...ith HIV/AIDS. Due to introduction of the,Partec i...
(Date:11/26/2008)...ed to 406 Subjects , , FRANKLIN, Mass., Nov...TC Bulletin Board: PLCSF) announced today that it ...Drug Administration (FDA) for its U.S. pivotal tri...alGuard System(TM) and associated therapy in the ..., , The FDA also approved PLC,s request to ...
(Date:11/25/2008)...ANCISCO, Calif., Nov. 25 ... a biopharmaceutical company focused on,innovativ... be exploring,strategic alternatives for its prec...ompany to focus its resources on the clinical deve..., and to support the initial commercialization of,...
Breaking Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3STERIS Corporation Announces New 24300 Million Share Repurchase Authorization 14383 1STERIS Corporation Announces New 24300 Million Share Repurchase Authorization 14383 2STERIS Corporation Announces New 24300 Million Share Repurchase Authorization 14383 3SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA Rich Safflower Oil 3970 1SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA Rich Safflower Oil 3970 2SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA Rich Safflower Oil 3970 3The ABCs of childhood zs 3A Snoring may be chronic despite surgery 14382 1The ABCs of childhood zs 3A Snoring may be chronic despite surgery 14382 2Low exposure to asbestos like mineral from Montana vermiculite may up lung disease risk 2504 1Low exposure to asbestos like mineral from Montana vermiculite may up lung disease risk 2504 2
...ll/ - Research,collaborators with Oncolytics Biote...poster presentation covering REOLYSIN(R),clinical ...ology,(ASCO) Annual Meeting, to be held June 1-5, ...ncolytics, U.K. Phase I systemic,administration tr...ase I Study of,Wild-Type Oncolytic Reovirus Admini...
...007 - A therapeutic,vaccine developed by the Germa...ew hope for cancer patients. The results of a,succ...d to an,international audience at the Annual Confe...y (ASCO) in Chicago, USA. ASCO is the,most importa...,world-wide., The active substance VPM4001, an imm...
Other Medicine Technology:Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2Vakzine Projekt Management Reports Positive Clinical Trial Results,With Their Therapeutic Prostate Cancer Vaccine VPM4001 2
...e BP monitor is designed to automatically measure ...BP along with heart rate. It's a Blood Pressure mo...ergometer and pharmacological stress test environm...ronments., ,Tango excels where other BP monit...
BD Visiswab Cotton Swab
...l, Philips Zymed 1810 Series offers retrospective ... the operator the flexibility to adjust the algori...application beyond the basic 1810 and you have eve...matic style that best meets the challenges of each...
...s STG for PC captures, displays, replays and analy...be effective in evaluating heart illnesses, pneumo...ase.,It provides objective evidence as a complem...time-expanded waveform displays, Phonocardiogra...
Medicine Products: